SCHEMBL894048

SCHEMBL894048

CC(C)(C)N(C(=O)O)[C@@H](Cc1ccc(-c2ccccn2)cc1)C[C@H](O)[C@@H](N)Cc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UGT1A1 P22309 3/20 0.44
NR1I2 O75469 2/20 0.44
MLNR O43193 1/20 0.44
SLCO2B1 O94956 1/20 0.44
ABCB11 O95342 1/20 0.44
ABCB1 P08183 1/20 0.44
CCKAR P32238 1/20 0.44
OPRK1 P41145 1/20 0.44
GHSR Q92847 1/20 0.44
SLCO1B3 Q9NPD5 1/20 0.44
ABCG2 Q9UNQ0 1/20 0.44
SLCO1B1 Q9Y6L6 1/20 0.44
DPP4 P27487 1/20 0.43
KCNH2 Q12809 2/20 0.39
TPH1 P17752 1/20 0.38
BRS3 P32247 3/20 0.37
GPR88 Q9GZN0 1/20 0.36
NMBR P28336 1/20 0.36
GRPR P30550 1/20 0.36
CTSD P07339 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2438701 1.00 UGT1A1 (0.44) UGT1A1NR1I2MLNRSLCO2B1ABCB11
SCHEMBL2434993 0.88 TPH1 (0.36) UGT1A1NR1I2MLNRSLCO2B1ABCB11
SCHEMBL2436156 0.87 UGT1A1 (0.45) UGT1A1NR1I2MLNRSLCO2B1ABCB11
SCHEMBL893379 0.86 CSNK1E (0.44) OPRK1RENSLC15A1
SCHEMBL2436403 0.85 DPP4 (0.42) UGT1A1NR1I2MLNRSLCO2B1ABCB11
SCHEMBL2435658 0.84 UGT1A1 (0.44) UGT1A1NR1I2MLNRSLCO2B1ABCB11
SCHEMBL2440909 0.84 UGT1A1 (0.44) UGT1A1NR1I2MLNRSLCO2B1ABCB11
SCHEMBL2435554 0.84 UGT1A1 (0.44) UGT1A1NR1I2MLNRSLCO2B1ABCB11
SCHEMBL2434389 0.83 MMP12 (0.41) GPR88REN
SCHEMBL2435094 0.83 DPP4 (0.43) UGT1A1NR1I2MLNRSLCO2B1ABCB11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140243340-A1 CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF ABBVIE INC. (US) 2014-08-28 US disclosed
US-20120083490-A1 CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF ABBOTT LABORATORIES (US) 2012-04-05 US disclosed
EP-2081917-A2 CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF Abbott Laboratories (US) 2009-07-29 EP disclosed
WO-2008027932-A2 CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF ABBOTT LABORATORIES (US) 2008-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120083490-A1 CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF CYP3A43, CYP3A5, POR UGT1A1 35/4885NR1I2 327/4885MLNR 1233/4885
US-20140243340-A1 CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF CYP3A43, CYP3A5, POR UGT1A1 35/4885NR1I2 327/4885MLNR 1233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.